Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV

Clinical Infectious Diseases

Volumn 68, Issue 11, 2019, Pages 1823-1830

  Evans, Scott R ^a   Tran, Thuy Tien T ^a   Hujer, Andrea M ^b,c   Hill, Carol B ^d   Hujer, Kristine M ^b,c   Mediavilla, Jose R ^e   Manca, Claudia ^e   Domitrovic, T Nicholas ^b,c   Perez, Federico ^b,c   Farmer, Michael ^f   Pitzer, Kelsey M ^f   Wilson, Brigid M ^c   Kreiswirth, Barry N ^e   Patel, Robin ^g   Jacobs, Michael R ^b   Chen, Liang ^e   Fowler, Vance G ^d   Chambers, Henry F ^h   Bonomo, Robert A ^b,c,i  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^f Opgen   (United States)

^g MAYO CLINIC   (United States)

^h SAN FRANCISCO GENERAL HOSPITAL   (United States)

ⁱ LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

Antimicrobial Resistance; Ceftazidime Avibactam; Ceftolozane Tazobactam; Pseudomonas Aeruginosa

Indexed keywords

AVIBACTAM PLUS CEFTAZIDIME; AZTREONAM; CEFEPIME; CEFTAZIDIME; CEFTOLOZANE; CEFTOLOZANE PLUS TAZOBACTAM; CIPROFLOXACIN; COLISTIN; DORIPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; TICARCILLIN; TOBRAMYCIN; ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; TAZOBACTAM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CARBAPENEM RESISTANCE; DIAGNOSTIC ACCURACY; DRUG USE; GENETIC PROFILE; HEALTH CARE ASSOCIATED PNEUMONIA; HUMAN; NONHUMAN; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SENSITIVITY AND SPECIFICITY; UPREGULATION; BETA-LACTAM RESISTANCE; DRUG COMBINATION; DRUG EFFECT; GENOTYPE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANCE; PROCEDURES;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAM RESISTANCE; BETA-LACTAMASE INHIBITORS; CEFTAZIDIME; CEPHALOSPORINS; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SENSITIVITY AND SPECIFICITY; TAZOBACTAM;

EID: 85066818923     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy801     Document Type: Article

References (15)

1. Mac Vane SH. Antimicrobial resistance in the intensive care unit: A focus on gram-negative bacterial infections. J Intensive Care Med 2017; 32:25-37.
2. Wolter DJ, Lister PD. Mechanisms of -lactam resistance among Pseudomonas aeruginosa. Curr Pharm Des 2013; 19:209-22.
3. Papp-Wallace KM, Bonomo RA. New -lactamase inhibitors in the clinic. Infect Dis Clin North Am 2016; 30:441-64.
4. Cabot G, Bruchmann S, Mulet X, et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of Amp C. Antimicrob Agents Chemother 2014; 58:3091-9.
5. Takeda S, Ishii Y, Hatano K, Tateda K, Yamaguchi K. Stability of FR264205 against Amp C beta-lactamase of Pseudomonas aeruginosa. Int J Antimicrob Agents 2007; 30:443-5.
6. Van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: Second-generation -lactam/-lactamase inhibitor combinations. Clin Infect Dis 2016; 63:234-41.
7. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare Clin Infect Dis 2002; 34:634-40.
8. Satlin MJ, Chen L, Patel G, et al. Multicenter clinical and molecular epidemiological analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States. Antimicrob Agents Chemother 2017; 61:e02349-16.
9. Evans SR, Hujer AM, Jiang H, et al.; Antibacterial Resistance Leadership Group. Rapid molecular diagnostics, antibiotic treatment decisions, developing approaches to inform empiric therapy: PRIMERS I and II. Clin Infect Dis 2016; 62:181-9.
10. Evans SR, Hujer AM, Jiang H, et al. Informing antibiotic treatment decisions: Evaluating rapid molecular diagnostics to identify susceptibility and resistance to carbapenems against Acinetobacter spp. in PRIMERS III. J Clin Microbiol 2017; 55:134-44.
11. Perez F, Hujer AM, Marshall SH, et al. Extensively drug-resistant Pseudomonas aeruginosa isolates containing bla VIM-2 and elements of Salmonella genomic island 2: A new genetic resistance determinant in northeast Ohio. Antimicrob Agents Chemother 2014; 58:5929-35.
12. CLSI Performance Standards for Antimicrobial Susceptibility Testing. 28th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute, 2017.
13. Mercaldo ND, Lau KF, Zhou XH. Confidence intervals for predictive values with an emphasis to case-control studies. Stat Med 2007; 26:2170-83.
14. Evans SR, Pennello G, Pantoja-Galicia N, et al.; Antibacterial Resistance Leadership Group. Benefit-risk evaluation for diagnostics: A framework (BEDFRAME). Clin Infect Dis 2016; 63:812-7.
15. Evans S, Ting N. Fundamental Concepts for New Clinical Trialists. Boca Raton, FL: Chapman & Hall/CRC Press Biostatistics Series, 2015.